Kristen Spencer, DO
Medical Oncology · New Brunswick, NJNPI 1720400906
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $38,132 of the $50,169 with a category attached, or 76.0%. 16 manufacturers reported payments, led by AstraZeneca at 30.6% of the total. 2025 is the largest year on record at $20,877, more than ten times the $261 reported in 2019.
Across 59 payments — averaging $850.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Jazz Pharmaceuticals Inc.$9K
- Helsinn Therapeutics (U.S.), Inc.$8K
- Genentech USA, Inc.$2K
- Exelixis Inc.$2K
- plus $3K from 10 others
Across 534 payments — averaging $13,417 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$2.6M
- Exelixis Inc.$1.5M
- Merck$663K
- Incyte Corporation$471K
- Eli Lilly$364K
- Boehringer Ingelheim International GmbH$325K
- plus $1.3M from 14 others
What the payments were for
- Consulting fees$38,13276%
- Speaking & faculty fees$4,80010%
- Travel & lodging$4,2769%
- Food & beverage$2,9616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $15,343 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $10,229 |
| Jazz Pharmaceuticals Inc. | 3 | $9,202 |
| Helsinn Therapeutics (U.S.), Inc. | 5 | $8,340 |
| Genentech USA, Inc. | 12 | $2,099 |
| Exelixis Inc. | 1 | $1,800 |
| Caris MPI, Inc. | 3 | $1,750 |
| Merck | 1 | $500 |
| Foundation Medicine, Inc. | 1 | $229 |
| Beone Medicines USA, Inc. | 2 | $164 |
| Array Biopharma Inc | 1 | $139 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Mirati Therapeutics, Inc. | 1 | $109 |
| Ipsen Biopharmaceuticals, Inc | 1 | $92 |
| GSK | 1 | $34 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FRUZAQLA$10,132
- ZIIHERA$9,064
- TRUSELTIQ$8,200
- IMFINZI$3,745
- Cabometyx$1,800
- MI CANCER SEEK$1,750
- Avastin$389
- FOUNDATIONONE CDX$229
- TECENTRIQ$150
- KRAZATI$109
How this compares
$50,169 in reported general payments places this provider in the 85th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New Brunswick
- Sarah WeissNew Brunswick$30K
- Missak HaigentzNew Brunswick$30K
- Patrick BolandNew Brunswick$29K
- Shridar GanesanNew Brunswick$27K
- Roman GroisbergNew Brunswick$22K
- Deborah ToppmeyerNew Brunswick$21K
- Morana VojnicNew Brunswick$16K
- Sanjay GoelNew Brunswick$13K
- Tina MayerNew Brunswick$10K
- Joseph AisnerNew Brunswick$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.